15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...
23:13 , Sep 15, 2017 |  BC Extra  |  Financial News

Bavarian Nordic plummets on Phase III CRPC failure of ProstVac

Bavarian Nordic A/S (CSE:BAVA) sank DKK213.50 (48%) to DKK230, losing DKK6.8 billion ($1.1 billion) in market cap, on Friday after an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer (CRPC) based on a preplanned interim analysis. The primary...
23:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis. The primary endpoint...
12:08 , May 24, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on six genomic loci could help predict the risk of primary biliary cholangitis. Genome-wide association studies in 2,029 PBC patients and 6,163 healthy volunteers from the Han Chinese population identified independent associations...
21:50 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

ProstVac: Ph I/II started

Bavarian Nordic said NCI investigators began an open-label, U.S. Phase I/II trial to evaluate ProstVac plus Opdivo nivolumab and Yervoy ipilimumab in about 65 patients. The Phase I portion will enroll 10 patients with castration-resistant...
20:10 , Mar 24, 2017 |  BC Week In Review  |  Company News

Bavarian Nordic, Roche deal

Bavarian Nordic will conduct a Phase II bladder cancer trial combining its CV301 with Roche’s Tecentriq atezolizumab. Both companies will share data from the trial, which is slated to begin around YE17. The Phase II...
21:59 , Jan 5, 2017 |  BC Week In Review  |  Clinical News

CV-301: Ph I/II started

Bavarian Nordic began an open-label, U.S. Phase I/II trial of CV-301 in about 120 patients who have failed prior therapy. The dose-escalation Phase I portion will evaluate CV-301 alone in 40 patients and the Phase...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said investigators began an open-label, U.S. Phase II trial to evaluate subcutaneous ProstVac and IV Yervoy ipilimumab each as monotherapy or in combination in 75 patients undergoing radical prostatectomy. Patients will receive ProstVac...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said the NCI began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate subcutaneous ProstVac given on days 0, 14, 28, 56, 84, 112 and 140 in about 90 patients undergoing active surveillance....